Clinical trials: Perimenopausal Bone Loss
Osteoporosis, Postmenopausal Osteoporosis
MK-5442 in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With an Oral Bisphosphonate (MK-5442-012)
This study seeks to demonstrate that additional gain in bone mineral density (BMD) can be achieved by switching to MK-5442 from an oral bisphosphonate in participants who have been receiving oral bisphosphonate therapy for at…
- Trial name
- NCT00996801
- Testing
- MK-5442, Alendronate Sodium, Vitamin D3
- Volunteers
- 526 people
- Sponsor
- Merck Sharp & Dohme LLC